Aclaris Therapeutics (ACRS) Gross Margin (2017 - 2026)

Aclaris Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 80.21% for Q1 2026.

• In Q1 2026, Gross Margin rose 1499.0% year-over-year to 80.21%; the TTM figure through Mar 2026 stood at 76.34% (down 966.0% YoY), while the FY2025 annual figure was 73.28%, down 1180.0% from the prior year.
• Gross Margin was 80.21% for Q1 2026 at Aclaris Therapeutics, up from 58.92% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 95.87% in Q4 2023 to a low of 20.51% in Q1 2022.
• Historically, Gross Margin has averaged 71.38% across 5 years, with a median of 77.44% in 2024.
• The sharpest annual moves came in 2022 and 2025: Gross Margin soared 6524 bps in 2022, then sank 3343 bps in 2025.
• A 5-year view of Gross Margin shows it stood at 88.69% in 2022, then increased by 8 bps to 95.87% in 2023, then declined by 4 bps to 92.35% in 2024, then tumbled by 36 bps to 58.92% in 2025, then surged by 36 bps to 80.21% in 2026.
• The last three Gross Margin figures came in at 80.21% (Q1 2026), 58.92% (Q4 2025), and 83.69% (Q3 2025), per Business Quant data.